RecruitingNot ApplicableNCT05813093

Interleaved TMS-fMRI in Ultra-treatment Resistant Depression

Interleaved TMS-fMRI to Evaluate Intermittent Theta-burst and Dorsolateral Prefrontal Circuit Engagement in Ultra-treatment Resistant Depression


Sponsor

Sunnybrook Health Sciences Centre

Enrollment

88 participants

Start Date

Sep 27, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

This is a study that will recruit patients from the neurosurgery clinic and the regular TMS clinic. It's a smaller study designed to collect brain imaging pre-treatment and then use image guided TMS to treat patient with a one week "accelerated" rTMS protocol using the research TMS machine that is housed in Dr. Sean Nestor's lab. The idea is to examine whether severe treatment resistant depression has a different brain signature than less severe/TRD and whether the investigators can get a therapeutic response from patients that would otherwise undergo neurosurgery or will ultimately undergo neurosurgery.


Eligibility

Min Age: 20 YearsMax Age: 65 Years

Inclusion Criteria4

  • Age 20-65
  • Have a diagnosis of MDD or persistent depressive disorder and meet criteria for a major depressive episode (moderate-severe) according to the DSM 5.0 with a 17-item Hamilton Rating Scale Score in Depression (HRSD-17) of >=18
  • UTRD subjects will also have a duration of depressive symptoms >=5 years, treatment resistance to antidepressants will be defined by Maudsley-staging, failing >6 antidepressants (level 4) and >1 adjunctive antidepressants of adequate dose/duration, failed at >=1 psychotherapy, and no response to >=1 trial of esketamine, IV ketamine, ECT or rTMS
  • Milder TRD participants will have failed at least 1 antidepressant medication of adequate dose/duration and never had neuromodulation treatment

Exclusion Criteria8

  • Contraindications to MRI
  • Medical/psychiatric co-morbidities that prevent participation in the study or where depression is not the primary psychiatric symptom of concern
  • History of psychosis, pregnancy, substance dependence within the last 6 months
  • Active neurological disorder
  • History of seizure disorder
  • Cognitive impairment
  • Unable to provide informed consent on their own
  • Pregnant

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICErTMS

Accelerated iTBS treatment


Locations(1)

Sunnybrook Health Sciences Centre

Toronto, Ontario, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05813093


Related Trials